FREMONT, CA, United States
FREMONT, CA, United States

Time filter

Source Type

Patent
Arbor Vita Corporation and Becton Dickinson | Date: 2015-11-04

Methods for producing a protein extract from cells, such as cells or cellular samples containing viral proteins, are provided. In general terms, the methods may involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent such as a polyoxyethylene alkyl ether, neutralizing the pH of the intermediate composition to produce the protein extract. Such methods can be used in conjunction with methods for detecting one or more target proteins in a sample, such as viral proteins. Systems, kits and compositions for practicing the subject methods are also provided.


Patent
Arbor Vita Corporation and Becton Dickinson | Date: 2015-01-15

Methods for producing a protein extract from cells, such as cells containing viral proteins, are provided. In general terms, the methods involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent, neutralizing the pH of the intermediate composition to produce the protein extract. Kits and compositions for practicing the subject methods are also provided.


Patent
Arbor Vita Corporation and NONO Inc | Date: 2012-09-14

The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.


Patent
Arbor Vita Corporation and NONO Inc | Date: 2011-07-19

The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.


Patent
Arbor Vita Corporation | Date: 2014-06-20

The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.


Patent
Arbor Vita Corporation | Date: 2014-06-16

The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.


Patent
Arbor Vita Corporation | Date: 2012-04-04

The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).


Patent
Arbor Vita Corporation | Date: 2012-08-29

The present application describes methods for detecting influenza A and/or influenza B and/or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and/or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 296.99K | Year: 2012

DESCRIPTION (provided by applicant): Cervical cancer is the leading cause of cancer-related death in women. It causes over 250,000 death world-wide / year, with 80% occurring in countries without systematic cervical neoplasia screening programs5. High risk Human Papillomavirus (HPV) infection is responsible for gt99% of all the cervical cancers4. Early detection of HPV infection by the Pap Test has reduced the death toll in developed nations significantly10. Despite its merits, the Pap Test is no longer considered an adequate screening technology due to the high false-negative and false-positive rates as a result of subjective visual interpretation of cell morphology by pathologists7. In recent years, several nucleic acid-based HPV diagnostic tests have emerged8. These tests have excellent clinical sensitivity, but fail to provide the desired clinical specificity, due to the high prevalence of HPV infection without pathological outcome8. Consequently, utilization of molecular HPV tests for screening may lead to costly over-treatment of patients (follow-up visits; colposcopies; biopsies). In response to the need for a specific yet sensitive screening method, Arbor Vita Corporation proposes the development of a diagnostic test that detects the Papillomavirusprotein E6, a pivotal oncoprotein in cervical oncogenesis. E6 oncoprotein levels in cervical swab specimens from patients with neoplasia correlate positively with the severity of lesions6. Accordingly, an HPV-E6 oncoprotein-based screening test has the potential to identify HPV-positive women who are at risk to develop cervical cancer amidst the much larger number of women with clinically irrelevant HPV infection. In this grant, the applicants propose the development of a high-throughput bead-based assay todetect and to type E6 oncoproteins from 15 high-risk HPV types for use in centralized clinical labs. The new HPV-E6 oncoprotein test will harness the technological advances in bead-based immunoassays and the availability of highly specific HPV-E6 monoclonal antibodies at Arbor Vita to achieve the desired high sensitivity, specificity and capability for automation. Under phase 1, our approach is focused on the development of the bead-based 15 HPV type E6 oncoprotein diagnostic prototype test. Upon successful completion of phase 1, the applicants will submit a phase 2 grant application for further product development towards the final format of the test that will be used in clinical studies for design validation. PUBLIC HEALTH RELEVANCE: Cervical cancer is caused by HPV and is worldwide a leading cause of death in women; implementation of sensitive and specific screening technology is the key to reduced mortality. The Pap Test screening method is no longer considered adequate. The applicants proposethe development of an HPV-E6 oncoprotein based test for cervical neoplasia screening. Via detection of E6, the cancer causing agent, the technology promises to identify those women who need clinical attention, among many more women who have HPV infection without clinical outcome. This should translate to public heath cost-saving by reducing the number of unnecessary clinical follow-up and treatment.


The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

Loading Arbor Vita Corporation collaborators
Loading Arbor Vita Corporation collaborators